Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin monotherapy in partially platinum-sensitive recurrent ovarian cancer
2015-002411-14Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in Malignant Ovarian Tumor and ovarian cancer, sponsored by Policlinico Gemelli. Primary endpoint: Objective response rate by RECIST 1.1. Started Nov 2020; status: terminated.
02
Drugs
trabectedin
03
Conditions
Malignant Ovarian Tumorovarian cancer
Beyond the preview
Go deeper on 2015-002411-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002411-14.